Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.
Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
